Millipore - Alfa Laval and Millipore Sign Joint Marketing Agreement To Integrate Centrifugation with Depth Filtration

Alfa Laval and Millipore Sign Joint Marketing Agreement To Integrate Centrifugation with Depth Filtration

BILLERICA, MA and RICHMOND, VA —July 28, 2003 —Alfa Laval Inc., a global leader in high-speed separators, and Millipore Corporation (NYSE: MIL), a multinational bioscience company, today announced a USA joint marketing agreement for Millipore’s multi-layer Millistak+^® HC depth filters and Alfa Laval’s high-speed biotechnology centrifuges. This integration of equipment will allow the efficient recovery of biopharmaceutical proteins generated by cell culture and fermentation.

“The first steps in drug recovery after a bioreactor are often the most challenging and require a series of separation and filtration steps. In working with a leader like Millipore, we are able to provide our customers with an optimal solution for primary recovery,” said Kirk Spitzer, president and CEO at Alfa Laval Inc.

Under the terms of the agreement, each company will exclusively promote the other company’s products to customers requiring centrifugation and depth filtration. Furthermore, this partnership encompasses assistance with sales activities, preparation and publication of technical articles, joint field testing and customer demonstrations of this centrifugation and depth filtration combination.

“The expertise from both companies will speed the drug development process and enhance customer process economics. Integrating and optimizing the key technologies of centrifugal separation and depth filtration will improve customers’ process efficiency, lower capital costs and reduce operating costs,” said Susan Vogt, president of Millipore’s BioPharmaceutical division.

Millipore’s Millistak+ HC depth filters combine two distinct separation technologies–charged depth media and membrane–to enhance filter capacity and retention. Designed for removing whole cells or colloidal particulates in mammalian cell culture applications, Millistak+ HC filters compress multiple stages of downstream bioreactor processes into one efficient step. Available in multiple formats and sizes, they are ideal for small batch processing and direct scale-up to large volume commercial production.

###

About Millipore
Millipore is a multinational, bioscience company that provides technologies, tools and services for the discovery, development and production of new therapeutic drugs. It serves the life science research, biotechnology and pharmaceutical industries. For more information about Millipore visit www.millipore.com.

About Alfa Laval Inc.
Alfa Laval, with global headquarters in Lund, Sweden, is a leading global provider of specialized products and engineering solutions. The equipment, systems and service are dedicated to assisting customers in optimizing the performance of their processes. The company helps their customers to heat, cool, separate and transport products such as oil, water, chemicals, beverages, foodstuff, starch and pharmaceuticals. Alfa Laval is a global market leader with its three key technologies – Centrifugal Separation, Heat Transfer and Fluid Handling.

For more information, visit www.alfalaval.us.

Millipore Forward Looking Statement Disclaimer
The matters discussed herein, as well as in future oral and written statements by management of Millipore Corporation that are forward-looking statements, are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Potential risks and uncertainties that could affect Millipore's future operating results include, without limitation, foreign exchange rates; regulatory delay in the approval of new therapeutics; further consolidation of drug manufacturers; competitive factors such as new membrane technology; lack of availability of raw materials or component products on a timely basis; inventory risks due to shifts in market demand; change in product mix; conditions in the economy in general and in the bioscience markets in particular; potential environmental liabilities; the inability to utilize technology in current or planned products due to overriding rights by third parties; difficulties inherent in research and development activities; and the risk factors listed from time to time in Millipore's filings with the SEC.

Millistak+ and Millipore are registered trademarks of Millipore Corporation

For immediate release

Media Contact:
Tom Anderson
Vice President, Corporate Communications
Millipore Corporation
781-533-2225 or 800-225-3384
Thomas_Anderson@Millipore.com

Doug Osman
Director of Life Sciences
Alfa Laval Inc.
804-236-1378
doug.osman@alfalaval.com

Investor Contact:
Geoffrey Helliwell
Treasurer
Millipore Corporation
781-533-2032 or 800-225-3384
Geoffrey_Helliwell@Millipore.com

Kirk Spitzer
President and CEO
Alfa Laval Inc.
804-545-8121
kirk.spitzer@alfalaval.com

Sustainability

Our commitment to environmental stewardship.

» More

Find A Location

Find the Millipore office or expert closest to you.

Contact Us

We want to hear from you. Contact a specific department below or click "Suggestions and Feedback" to send your comments.